Drug Industry Calls For EU Action Against French Off-Label Law
This article was originally published in SRA
Executive Summary
The European pharmaceutical industry has filed a second complaint with the European Commission against national legislation allowing the off-label use of cheaper medicines where approved alternatives exist, for purely financial reasons1.
You may also be interested in...
EU Study Revives Industry Attacks On Promotion Of Off-Label Use To Save Money
A study for the European Commission explores in detail the drivers behind off-label use of medicines in EU countries, but the pharmaceutical industry would have liked it to speak out against national authorities’ promotion of off-label uses for economic reasons.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.